Featured Clinical Trials
Learn what’s coming down the research pipeline, and find breast cancer clinical trials you may be eligible to participate in.
Researchers seek 500 women who have hormone receptor-positive, HER2-negative advanced breast cancer to take part in a phase III study testing a new medicine pair. Women who are postmenopausal, or no longer get their periods, may qualify to enroll in the study if they have not yet received treatment for advanced breast cancer.
Researchers seek 306 people with metastatic, HER2-negative breast cancer and who tested positive for either a BRCA1 or BRCA2 mutation to take part in a treatment study. The trial team will assess the survival benefit and safety of niraparib, an oral PARP inhibitor, compared with physicians’ choice of standard chemotherapy.
Researchers seek 880 men and women with metastatic breast cancer who have a primary tumor still in the breast for a study designed to find out if removing it lengthens survival. The primary tumor is the first tumor in the breast. Cancer cells from the primary tumor can spread to other parts of the body, causing metastatic disease.
Researchers from the National Surgical Breast and Bowel Project seek women with early-stage, HER2-low breast cancer for a phase III study. The trial team is exploring whether adding trastuzumab (Herceptin) to combination chemotherapy improves invasive disease-free survival.
Researchers seek participants with early-stage, HER2-positive breast cancer for a phase III study. The trial team will explore which of two anti-HER2 medicines results in the longest invasive disease-free survival.
Researchers seek 48 women for a small, phase IB study of ONT-380, a new anti-HER2 medicine that can be taken by mouth. The pill will be given along with the standard amount of T-DM1, by vein.
Researchers seek postmenopausal women with hormone-positive breast cancer for a clinical trial exploring whether daily doses of an antidepressant lessens pain related to the use of hormonal therapies, when compared to women who take no pain medicines.
Researchers seek women diagnosed with invasive, early-stage, hormone-positive breast cancer to enroll in a phase III study.
The BROCADE study needs men and women with metastatic breast cancer and a BRCA1 or BRCA2 gene mutation for a phase II clinical trial. The trial team will assess how safe and effective a new targeted therapy is when combined with one or more common chemotherapy medicines.
Researchers seek 240 women with metastatic, triple-negative breast cancer for a phase II study assessing the safety of different chemotherapy combinations and how well they prevent the worsening of the disease.